2071-LB: Reduced Risk of Obesity-Related Cancers with Real-World Weight Loss

IF 6.2 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes Pub Date : 2024-06-21 DOI:10.2337/db24-2071-lb

KENDA ALKWATLI, HUIJUN XIAO, ARSHIYA MARIAM, KEVIN M. PANTALONE, DANIEL M. ROTROFF

{"title":"2071-LB: Reduced Risk of Obesity-Related Cancers with Real-World Weight Loss","authors":"KENDA ALKWATLI, HUIJUN XIAO, ARSHIYA MARIAM, KEVIN M. PANTALONE, DANIEL M. ROTROFF","doi":"10.2337/db24-2071-lb","DOIUrl":null,"url":null,"abstract":"Objective: To assess whether real-world weight loss is associated with a modified risk of developing cancer. Methods:A retrospective observational study was conducted using the electronic health record at Cleveland Clinic (1/1/00-12/31/22). The primary endpoint was the development of 13 obesity-related cancers, and the secondary endpoint was the occurrence of 17 other types of cancer. The association between the % change in body mass index (BMI) 3, 5, and 10 year intervals prior to cancer diagnosis (for cases) vs. controls for each cancer endpoint was assessed using logistic regression models. Results:A total of 105,489 patients:100,162 controls and 5327 cases were identified. The % female was 43% and 52%, the % White was 84% and 78%, and median age (years) was 62 and 53, among cases and controls, respectively. Median BMI at censoring (kg/m2.) was 34.3 for cases and 34.5 for controls. Our results show reduced risk of developing obesity-related cancers with weight loss at 3 years (OR 0.99, 95%CI [0.984, 0.996]) and 5 years (OR 0.989,95% CI [0.983-0.995]), and for other types of cancer for all time intervals (ORs&lt;1, P &lt;0.001) (Figure 1a). The risk was reduced for renal cell carcinoma (3 years), multiple myeloma (10 years), and endometrial cancer (3& 5years) among primary cancer endpoints (P&lt;0.05) (Figure 1b). Conclusion:A decrease in risk of developing obesity-related cancers and other types of cancer was associated with real-world weight loss. Disclosure K. Alkwatli: None. H. Xiao: None. A. Mariam: None. K.M. Pantalone: Speaker's Bureau; AstraZeneca. Consultant; AstraZeneca. Board Member; Bayer Inc. Research Support; Bayer Inc. Speaker's Bureau; Corcept Therapeutics. Consultant; Corcept Therapeutics, Diasome, Eli Lilly and Company, Merck & Co., Inc. Speaker's Bureau; Merck & Co., Inc. Research Support; Merck & Co., Inc. Consultant; Novo Nordisk. Research Support; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Research Support; Twin Health. Consultant; Sanofi. D.M. Rotroff: Consultant; Novo Nordisk. Research Support; Bayer Inc.","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"7 1","pages":""},"PeriodicalIF":6.2000,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2337/db24-2071-lb","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To assess whether real-world weight loss is associated with a modified risk of developing cancer. Methods:A retrospective observational study was conducted using the electronic health record at Cleveland Clinic (1/1/00-12/31/22). The primary endpoint was the development of 13 obesity-related cancers, and the secondary endpoint was the occurrence of 17 other types of cancer. The association between the % change in body mass index (BMI) 3, 5, and 10 year intervals prior to cancer diagnosis (for cases) vs. controls for each cancer endpoint was assessed using logistic regression models. Results:A total of 105,489 patients:100,162 controls and 5327 cases were identified. The % female was 43% and 52%, the % White was 84% and 78%, and median age (years) was 62 and 53, among cases and controls, respectively. Median BMI at censoring (kg/m2.) was 34.3 for cases and 34.5 for controls. Our results show reduced risk of developing obesity-related cancers with weight loss at 3 years (OR 0.99, 95%CI [0.984, 0.996]) and 5 years (OR 0.989,95% CI [0.983-0.995]), and for other types of cancer for all time intervals (ORs<1, P <0.001) (Figure 1a). The risk was reduced for renal cell carcinoma (3 years), multiple myeloma (10 years), and endometrial cancer (3& 5years) among primary cancer endpoints (P<0.05) (Figure 1b). Conclusion:A decrease in risk of developing obesity-related cancers and other types of cancer was associated with real-world weight loss. Disclosure K. Alkwatli: None. H. Xiao: None. A. Mariam: None. K.M. Pantalone: Speaker's Bureau; AstraZeneca. Consultant; AstraZeneca. Board Member; Bayer Inc. Research Support; Bayer Inc. Speaker's Bureau; Corcept Therapeutics. Consultant; Corcept Therapeutics, Diasome, Eli Lilly and Company, Merck & Co., Inc. Speaker's Bureau; Merck & Co., Inc. Research Support; Merck & Co., Inc. Consultant; Novo Nordisk. Research Support; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Research Support; Twin Health. Consultant; Sanofi. D.M. Rotroff: Consultant; Novo Nordisk. Research Support; Bayer Inc.

查看原文本刊更多论文

2071-LB：通过实际减肥降低肥胖相关癌症风险

目的评估现实世界中的体重减轻是否与癌症发病风险的改变有关。方法：利用克利夫兰诊所的电子健康记录（1/1/00-12/31/22）进行了一项回顾性观察研究。主要终点是 13 种与肥胖有关的癌症的发病率，次要终点是 17 种其他类型癌症的发病率。采用逻辑回归模型评估了癌症确诊前 3 年、5 年和 10 年的体重指数（BMI）变化百分比（病例）与对照组在每个癌症终点之间的关联。结果：共确定了 105,489 名患者：100,162 名对照组患者和 5327 名病例。病例和对照组中，女性比例分别为 43% 和 52%，白人比例分别为 84% 和 78%，中位年龄（岁）分别为 62 岁和 53 岁。病例和对照组在普查时的体重指数中位数（千克/平方米）分别为 34.3 和 34.5。我们的研究结果表明，体重减轻 3 年（OR 0.99，95%CI [0.984，0.996]）和 5 年（OR 0.989，95%CI [0.983-0.995]）后，患肥胖相关癌症的风险降低，所有时间间隔内患其他类型癌症的风险也降低（ORs<1，P <0.001）（图 1a）。在主要癌症终点中，肾细胞癌（3 年）、多发性骨髓瘤（10 年）和子宫内膜癌（3<5 年）的风险降低（P<0.05）（图 1b）。结论：患肥胖相关癌症和其他类型癌症的风险降低与实际体重减轻有关。披露 K. Alkwatli：无。H. Xiao：无：H. Xiao: None.A. Mariam：无：无。K.M. Pantalone：Speaker's Bureau; AstraZeneca.顾问；阿斯利康。董事会成员; Bayer Inc.研究支持；拜耳公司。Speaker's Bureau; Corcept Therapeutics.顾问；Corcept Therapeutics、Diasome、Eli Lilly and Company、Merck & Co.发言人；默克公司。默克公司研究支持。顾问；诺和诺德公司。研究支持；诺和诺德公司。发言人办公室；诺和诺德公司。研究支持；Twin Health。赛诺菲顾问D.M. Rotroff：诺和诺德公司顾问。研究支持；拜耳公司。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes 医学-内分泌学与代谢

CiteScore

12.50

自引率

2.60%

发文量

1968

审稿时长

1 months

期刊介绍： Diabetes is a scientific journal that publishes original research exploring the physiological and pathophysiological aspects of diabetes mellitus. We encourage submissions of manuscripts pertaining to laboratory, animal, or human research, covering a wide range of topics. Our primary focus is on investigative reports investigating various aspects such as the development and progression of diabetes, along with its associated complications. We also welcome studies delving into normal and pathological pancreatic islet function and intermediary metabolism, as well as exploring the mechanisms of drug and hormone action from a pharmacological perspective. Additionally, we encourage submissions that delve into the biochemical and molecular aspects of both normal and abnormal biological processes. However, it is important to note that we do not publish studies relating to diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus. Our aim is to provide a platform for research that contributes to advancing our understanding of the underlying mechanisms and processes of diabetes.